MOMichihiro Ono

Michihiro Ono

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michihiro Ono has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of Two Partially Covered Metal Stents for Endoscopic Ultrasound‐guided Hepaticogastrostomy: A Multi‐Center Retrospective Study

    by Masahiro Yamamura, Hirotoshi Ishiwatari, Saburo Matsubara, Takeshi Okamoto, Michihiro Ono, Toshinori Okuda, Etsuji Ishida, Kohichi Takada, Kazuma Ishikawa, Naoki Sasahira, et al.

    Objectives: Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) is an alternative biliary drainage method after failed endoscopic retrograde cholangiopancreatography. Nevertheless, it is associated with adverse events (AEs), including peritonitis and stent migration. The influence of metallic stent (MS) design characteristics, including axial force (AF), on the safety and efficacy of EUS‐HGS remains unclear. Methods: This multicenter retrospective study included patients with unresectable malignant biliary obstruction who underwent EUS‐HGS using either a high‐AF MS (Niti‐S biliary S‐type) or a low‐AF MS (EGIS biliary) between January 2019 and December 2022. Propensity score matching was performed in a 1:2 ratio. Outcomes included clinical success, early and late non‐recurrent biliary obstruction (non‐RBO) AEs, RBO, time to RBO (TRBO), and overall survival (OS). Results: After matching, 27 patients in the high‐AF group and 54 in the low‐AF group were analyzed. Clinical success, RBO rate, TRBO, OS, and late non‐RBO AE rates were similar between groups. However, early non‐RBO AEs were more frequent in the high‐AF group (37% vs. 13%, p = 0.02). Conclusions: Of the two partially covered MSs evaluated, the EGIS biliary stent demonstrated fewer early non‐RBO AEs after EUS‐HGS.

    • 1 March 2026
      • Vol. 9  (3) , e70504
    Open Access

    Successful Management of Suspected Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in BRAF-Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors: A Case Report.

    by Akira Shibata, Michihiro Ono, Shutaro Oiwa, Atsushi Uesugi, Seiya Saito, Makoto Usami, Tomoyuki Abe, Masahiro Yoshida, Masahiro Maeda, Kohichi Takada

    The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. However, the full spectrum of adverse events associated with the sequential use of these agents remains unclear. Hemophagocytic lymphohistiocytosis (HLH) is a fatal cytokine release syndrome that can be triggered by a cytokine storm. A 49-year-old man underwent left lateral hepatectomy and adjuvant chemotherapy for cholangiocarcinoma and subsequently developed lymph node recurrence. The patient initially received systemic chemotherapy with gemcitabine, cisplatin, and S-1; however, due to disease progression, the regimen was switched to gemcitabine, cisplatin, and durvalumab. After these treatments, a BRAF V600E mutation was identified through comprehensive gene panel testing, leading to the initiation of BRAF and MEK inhibitors. However, 3 months later, the patient presented to the emergency department of Steel Memorial Muroran Hospital with fever and fatigue in June 2024. He was initially diagnosed with septic shock but was unresponsive to broad-spectrum antibiotics. Laboratory tests revealed elevated ferritin levels, elevated soluble interleukin-2 receptor levels, and Epstein-Barr Virus (EBV)-DNA. HLH was diagnosed, and multidisciplinary treatment, including steroid pulse therapy, was initiated. The patient's condition improved dramatically, and he survived. We report a rare case of cholangiocarcinoma with suspected EBV-associated HLH that developed after sequential therapy with an ICI and BRAF/MEK inhibitors. Clinicians should consider HLH as a differential diagnosis in patients with a history of ICI therapy who present with severe unexplained inflammation or shock. Prompt diagnosis and multidisciplinary management are crucial to prevent death.

  • Open Access

    Successful Management of Suspected Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in BRAF ‐Mutant Cholangiocarcinoma Following Treatment With Immune Checkpoint Inhibitors and BRAF / MEK Inhibitors: A Case Report

    by Akira Shibata, Michihiro Ono, Shutaro Oiwa, Atsushi Uesugi, Seiya Saito, Makoto Usami, Tomoyuki Abe, Masahiro Yoshida, Masahiro Maeda, Kohichi Takada

    Background: The BRAF V600E mutation is a rare genetic alteration in cholangiocarcinoma for which sequential therapy with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors may be effective. However, the full spectrum of adverse events associated with the sequential use of these agents remains unclear. Hemophagocytic lymphohistiocytosis (HLH) is a fatal cytokine release syndrome that can be triggered by a cytokine storm. Case: A 49‐year‐old man underwent left lateral hepatectomy and adjuvant chemotherapy for cholangiocarcinoma and subsequently developed lymph node recurrence. The patient initially received systemic chemotherapy with gemcitabine, cisplatin, and S‐1; however, due to disease progression, the regimen was switched to gemcitabine, cisplatin, and durvalumab. After these treatments, a BRAF V600E mutation was identified through comprehensive gene panel testing, leading to the initiation of BRAF and MEK inhibitors. However, 3 months later, the patient presented to the emergency department of Steel Memorial Muroran Hospital with fever and fatigue in June 2024. He was initially diagnosed with septic shock but was unresponsive to broad‐spectrum antibiotics. Laboratory tests revealed elevated ferritin levels, elevated soluble interleukin‐2 receptor levels, and Epstein–Barr Virus (EBV)‐DNA. HLH was diagnosed, and multidisciplinary treatment, including steroid pulse therapy, was initiated. The patient's condition improved dramatically, and he survived. Conclusion: We report a rare case of cholangiocarcinoma with suspected EBV‐associated HLH that developed after sequential therapy with an ICI and BRAF/MEK inhibitors. Clinicians should consider HLH as a differential diagnosis in patients with a history of ICI therapy who present with severe unexplained inflammation or shock. Prompt diagnosis and multidisciplinary management are crucial to prevent death.


  • Open Access

    Endoscopic ultrasound-guided gallbladder drainage using a forward-viewing echoendoscope for Roux-en-Y reconstruction

    by Ono Michihiro, Oiwa Shutaro, Yokoyama Ryota, Saito Seiya, Uesugi Atsushi, Abe Tomoyuki, Maeda Masahiro

    Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) is an effective treatment option for high-risk surgical cholecystitis. However, Roux-en-Y (RY) reconstruction can be challenging because of the increased difficulty in reaching the duodenum [1]. Here, we report a case in which EUS-GBD was safely performed, using a forward-viewing echoendoscope (FV-EUS), in a patient with acute cholecystitis following RY reconstruction. A 92-year-old woman with a history of total gastrectomy and RY reconstruction was admitted to our hospital with acute cholecystitis ([Fig. 1]). She had an age-adjusted Charlson comorbidity index score of 6 and underwent percutaneous transhepatic gallbladder drainage (PTGBD). Choledocholithiasis was confirmed ([Fig. 2]); a double-balloon endoscopy-assisted endoscopic retrograde cholangiopancreatography was performed on day 8 ([Fig. 3]). Owing to a cystic duct stone, cholecystitis did not improve after PTGBD tube clamping ([Fig. 4]). Therefore, we performed EUS-GBD using an FV-EUS (TGF-UC260J; Olympus Medical Systems, Tokyo, Japan). After careful manipulation, the duodenum was reached within 9 min. Injection of contrast medium from the PTGBD tube allowed the identification of the gallbladder lumen, as visualized on ultrasound imaging, enabling puncture using a 19G needle (EZ-shot 3 plus; Olympus). A self-expandable metal stent (BONASTENT M-Intraductal; Medico’s Hirata Inc., Osaka, Japan) was introduced and deployed over a 0.035-inch stiff guidewire (RevoWave SeekMaster Hard; Piolax Medical Devices, Kanagawa, Japan) after dilation using an 8-mm balloon catheter (REN biliary dilation catheter; KANEKA, Osaka, Japan) ([Video 1]). Eight days later, the patient was discharged. A previously reported case of EUS-GBD following RY reconstruction with an oblique-viewing linear array echoendoscope highlighted the need for guidewire advancement [2]. The FV-EUS had greater flexibility and a shorter hard scope tip than that of the oblique-viewing echoendoscope ([Fig. 5]), improving insertion capability and safety [3] and eliminating the need for guidewire advancement. To our knowledge, this is the first report of EUS-GBD using an FV-EUS for RY reconstruction. Endoscopy_UCTN_Code_TTT_1AS_2AH Article published online: 25 September 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    Efficacy and safety of endoscopic ultrasound‐guided gallbladder drainage without dilation by using a 0.035‐inch stiff guidewire

    by Michihiro Ono, Yuki Ikeda, Ginji Ohmori, Yohei Arihara, Ryo Shibuya, Atsushi Uesugi, Shutaro Oiwa, Ryo Ito, Makoto Usami, Michiko Yamada, et al.

    Endoscopic ultrasound‐guided gallbladder drainage for patients with cholecystitis and high surgical risk is commonly performed by dilating the fistula before inserting the delivery sheath; however, this carries an increased risk of peritonitis. To overcome this problem, we developed a new technique that did not require dilation, using a 0.035‐inch stiff guidewire, and retrospectively evaluated the efficacy and safety of this technique. This retrospective case series report collected data on non‐surgical patients who underwent endoscopic ultrasound‐guided gallbladder drainage for various indications at Steel Memorial Muroran Hospital between November 2020 and October 2022. A total of 71 patients were included (mean age 83 ± 7.6 years; 33 women and 38 men). Breakthrough of the delivery sheath without dilation of the fistula was successful in 97.2% (n = 69) of patients. The success rate of stent placement was 98.6% (n = 70), as was the clinical success rate. Complications occurred in 2.8% (n = 2) of patients. Early and late adverse events occurred in 2.8% (n = 2) and 12.7% (n = 9) of patients, respectively. The mean procedure time was 24.8 ± 9.3 min. If a 0.035‐inch stiff guidewire is used, the dilation procedure can be omitted in the endoscopic ultrasound‐guided gallbladder drainage using self‐expandable metal stents.


  • Tissue acquisition for comprehensive genomic profiling of gallbladder cancer using a forward-viewing echoendoscope in a patient who underwent Roux-en-Y reconstruction

    by Michihiro Ono, Shutaro Oiwa, Atsushi Uesugi, Seiya Saito, Ryota Yokoyama, Makoto Usami, Tomoyuki Abe, Miri Fujita, Kohichi Takada, Masahiro Maeda

    A 50-year-old man with a history of total gastrectomy, distal pancreatectomy, splenectomy, and Roux-en-Y reconstruction was admitted to our hospital with a gallbladder tumor that had infiltrated the liver and abdominal wall. Because malignant cells were not collected during the percutaneous biopsy, we planned to perform an endoscopic ultrasound-guided fine-needle biopsy with a 22-G Franseen needle using a forward-viewing echoendoscope. Using intermittent manual compression, the forward-viewing echoendoscope reached the duodenum under fluoroscopic guidance. Endoscopic ultrasound-guided fine-needle biopsy was performed using a 22-G needle and 20-mL syringe and yielded a sufficient specimen with a single puncture. Malignant cells were promptly identified during on-site evaluation. The composition of the specimen (> 20% cancer cells and tissue area exceeding 25 mm2) enabled comprehensive genomic profiling. Subsequently, high-tumor mutational burden was diagnosed based on comprehensive genomic profiling, and pembrolizumab was initiated as a second-line therapy. Even in cases involving Roux-en-Y reconstruction, endoscopic ultrasound-guided fine-needle biopsy using a forward-viewing echoendoscope can result in collection of a high-quality specimen.


  • Open Access

    Endoscopic coagulation for massive bleeding from a gallbladder ulcer after endoscopic ultrasound-guided gallbladder drainage

    by Michihiro Ono, Shutaro Oiwa, Ryo Shibuya, Ginji Oomori, Yuki Ikeda, Tomoyuki Abe, Masahiro Maeda

    Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) is an effective treatment for high-risk surgical cholecystitis and its use is gradually becoming more widespread. According to meta-analyses, the frequency of bleeding is low (1.8–4.3 %) [1] [2]. We report a case of arterial bleeding from a gallbladder ulcer after EUS-GBD that was successfully cauterized endoscopically and hemostasis was achieved. An 85-year-old man, who had been admitted to another hospital with Parkinson’s disease and cerebral infarction, was transferred to our hospital with acute cholecystitis ([Fig. 1]). He was deemed high risk for surgery and had an age-adjusted Charlson Comorbidity Index score of 6. Therefore, he underwent EUS-GBD with a fully covered self-expandable metal stent (FCSEMS). Computed tomography (CT) performed the day after EUS-GBD showed insufficient space between the FCSEMS and gallbladder wall, and the FCSEMS was in contact with the gallbladder mucosa ([Fig. 2]). The patient was discharged and readmitted 68 days later for melena. Arterial phase CT showed a migrated FCSEMS and extravasation into the bile ducts ([Fig. 3]). An admission endoscopy revealed a clot at the fistula ([Fig. 4]). Following fistula dilation using a balloon catheter, an endoscope was inserted into the gallbladder. Although there was no active bleeding, a blood vessel was found at the ulcer, which we cauterized for 7 s ([Fig. 5]). Anemia progressed 12 days later, and a repeat endoscopy showed a large number of clots in the gallbladder. During clot removal, spurting bleeding was observed ([Video 1]). Hemostatic forceps were used to stop the bleeding, and cauterization was performed. No further bleeding occurred. Mechanical stimulation of the gallbladder wall by the FCSEMS may be considered a cause of gallbladder ulceration and hemorrhage; therefore, the FCSEMS should be placed in an area with sufficient space. Video 1 As the clots were removed, spurting bleeding was observed. Endoscopic coagulation was successful. Endoscopy_UCTN_Code_CPL_1AL_2AB Article published online: 24 February 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany